Warren J
Guidant Corporation, St. Paul, Minnesota 55112-5798, USA.
Am J Cardiol. 2000 Nov 2;86(9A):119K-125K. doi: 10.1016/s0002-9149(00)01297-2.
Since the first cardiac pacemaker was implanted in 1958, continuing technologic innovations have steadily improved the therapeutic power of implantable cardiac device therapy. This evolution has benefited both patients and their physicians, expanding the conditions manageable through pacing and implantable defibrillation while streamlining implant and follow-up procedures. This progress is likely to continue unabated because (1) devices will continue to grow smaller; (2) more advanced features will be introduced, with an increased level of automaticity; and (3) the quality and quantity of telemetered diagnostic information about both patient and device will continue to expand, and device sophistication will soon reach the point at which prediction and prevention of specific events will be a reality. This article reviews historical developments and presents concepts that are guiding future technologic innovations.
自1958年首例心脏起搏器植入以来,持续的技术创新稳步提升了植入式心脏设备治疗的疗效。这一发展使患者及其医生均受益,通过起搏和植入式除颤可管理的病症范围得以扩大,同时简化了植入和随访程序。这一进展可能会持续不减,原因如下:(1)设备将持续缩小;(2)将引入更先进的功能,自动化程度提高;(3)关于患者和设备的遥测诊断信息的质量和数量将继续增加,设备的复杂性很快将达到能够实现特定事件预测和预防的程度。本文回顾了历史发展并介绍了指导未来技术创新的概念。